INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 MicroRNA1005p inhibits osteoclastogenesis bone resorption regulating fibroblast growth factor 21 LONG ZHOU1 HANYI SONG2 LINLIN GAO3 LIYU YANG1 SHUAI MU1 QIN FU1 Departments 1Orthopedic Surgery 2Gastroenterology 3Animal Laboratory Experimental Research Center Shengjing Hospital China Medical University Shenyang Liaoning 110004 PR China Received July 31 2018 Accepted November 21 2018 DOI 103892ijmm20184017 Abstract MicroRNAs miRNAsmiRs posttranscriptional regulators serve important roles osteoclastogenesis bone metabolism roles miRNAs completely clarified The present study aimed investigate effects miR1005p mechanism liverbone endocrine metabolism A miRNA microarray analysis conducted evaluate miRNA expression profile receptor activator nuclear factorκB ligandstimulated osteoclastogenesis Hematoxylin eosin tartrateresistant acid phosphatase staining performed analyze trabecular bone microstructure osteoclast differentiation The mRNA protein expression levels assessed reverse transcriptionquantitative polymerase chain reaction western blotting respectively The results revealed vitro osteoclast differentiation vivo bone resorption suppressed miR1005p overexpression In vivo decrease miR1005p increase FGF21 simultaneously observed mice following ovariectomy OVX Bioinformatics analysis experimental data confirmed FGF21 direct target miR1005p Conversely augmentation miR1005p specific agomir OVXoperated mice decreased levels FGF21 serum liver prevented osteoclastogenesis bone loss The present study revealed FGF21 signal molecule associated mechanism liverbone endocrine metabolism targeted miR1005p In addition miR1005p serve important role protecting OVXinduced osteoporosis Correspondence Dr Qin Fu Department Orthopedic Surgery Shengjing Hospital China Medical University Floor 14 2nd Building 36 Sanhao Street Heping Shenyang Liaoning 110004 PR China Email fu_qin022163com Key words microRNA1005p fibroblast growth factor 21 ovariectomy osteoporosis osteoclastogenesis Introduction As dynamic metabolic bone modeling remodeling modulated major bone cells Osteoblasts able secrete bone matrix accelerate calcium Ca deposition osteoclasts responsible resolving mineralized bone matrix 13 In process bone mainte nance repair extracellular signaling transduction osteoblasts osteoclasts serves crucial role bone homeo stasis 4 For example osteoblastsecreted receptor activator nuclear factorκB NFκB RANK ligand RANKL binds RANK receptor osteoclasts promoting osteoclast survival osteoclastogenesis 5 In addition binding macrophage colonystimulating factor MCSF receptor colony stimulating factor receptor reported essential generation osteoclast precursor cells present prior RANKL stimulation 2 Furthermore tumor necrosis factor receptorassociated factor6activated NFκB signaling induces initialization nuclear factor activated T cells cytoplasmic 1 NFATc1 key transcription factor osteoclastogenesis stimulates expression osteoclastspecific genes including tartrateresistant acid phosphatase TRAP cathepsin K Ctsk calcitonin receptor 25 MicroRNAs miRNAsmiRs class small singlestranded noncoding RNA molecules 1824 nucleo tides length regulate gene expression translation targeting 3untranslated regions 3UTRs miRNAs serve novel class posttranscriptional regulators involved diverse biological functions 68 Previous studies reported miRNAs serve important roles regulating skeletal development 910 For example overexpression miR34a miR125a miR503 inhibits osteoclastogenesis rescue bone loss 91112 Conversely miR214 promotes osteoclastogenesis inhibits osteoblast differentiation bone formation 1013 miR100 member miR99 family 14 participates biological processes including chemotherapy resistance apoptosis osteogenic differentiation osteoporotic fractures 1518 However role miR100 ovariectomy OVXinduced osteopo rosis osteoclastogenesis remains unclear Fibroblast growth factor FGF21 member FGF family mainly expressed liver numerous metabolic functions 19 FGF21 demonstrated 728 ZHOU et al miR1005p INHIBITS BONE LOSS improve obesityassociated glucose lipid metabolic disor ders 20 renal dysfunction 21 cardiac hypertrophy 22 ethanolassociated liver injury 23 Conversely upregulation FGF21 independent risk factor associated severity nonalcoholic fatty liver disease 24 In dietinduced mouse model obesity reduction plasma FGF21 levels hepatic FGF21 resistance exenatide protects highfat dietinduced nonalcoholic fatty liver disease 25 Emerging evidence highlighted FGF21 serve potent regulator skeletal homeostasis 26 In Han Chinese population significant inverse correlation observed plasma FGF21 levels bone mineral density BMD femoral neck Wards triangle 27 An increase serum FGF21 levels negatively associated BMD bone mineral content human immunodeficiency virus1infected patients 28 However fasting plasma FGF21 levels healthy women exhibit strong positive association total BMD spine BMD 29 Notably FGF21knockout mice results highbonemass phenotype FGF21 gainoffunction decreases bone mass promotes osteoclastogenesis 2630 However underlying molecular mechanisms FGF21enhanced osteoclastogenesis bone resorption completely clarified The present study screened expression profile miRNAs process MCSF RANKLinduced osteoclastogenesis miRNA microarray The results demonstrated miR1005p downregulated functioned negative regulator osteoclastogenesis miR1005p gainoffunction significantly suppressed osteoclast activity vitro In vivo treatment agomirmiR1005p inhibited FGF21 expression osteoclast activity prevented bone loss mice following OVX Materials methods Cell culture The present study approved Animal Ethical Committee Shengjing Hospital China Medical University Shenyang China approval 2016PS361K Murine bone marrowderived macrophages BMMs obtained form female C57BL6J mice described previously 31 BMMs maintained αMinimum Essential Medium HyClone GE Healthcare Life Sciences Logan UT USA containing 10 fetal bovine serum FBS Gibco Thermo Fisher Scientific Inc Waltham MA USA 1 penicillinstreptomycin 37C atmosphere containing 5 CO2 Nonadherent cells cultured MCSF 50 ngml RD Systems China Co Ltd Shanghai China 3 days induce osteoclast precursors For osteoclast differentiation osteoclast precursors incubated MCSF 50 ngml RANKL 100 ngml RD Systems China Co Ltd 3 days Fig 1A Osteoclasts 3 nucleicell identified TRAPpositive cells The NCTC1469 mouse normal liver cell line serial number 3111C0001CCC000290 obtained Institute Biochemistry Cell Biology Chinese Academy Sciences National Infrastructure Cell Line Resource Shanghai China The cells cultured Dulbeccos modified Eagles medium Gibco Thermo Fisher Scientific Inc supplemented 5 FBS humidified incubator containing 5 CO2 95 air Thermo Fisher Scientific Inc Differentially expressed miRNAs RA NKLinduced osteoclast differentiation Osteoclast differentiation induced shown Fig 1A Subsequently miRNA expres sion profiling osteoclasts conducted mouse miRNA expression profiling array V2 Illumina Inc San Diego CA USA according manufacturers protocol Hierarchical clustering performed determine similarity complete linkage Euclidean distance MeV software version 426 httpmevtm4orgwelcome 32 The miRNAs foldchange 2 response RANKLstimulated osteoclast differentiation compared precursor cells selected determine expression profile Animal model Female C57BL6J mice age 8 weeks body weight 202 g obtained Animal Center Shengjing Hospital China Medical University allowed acclimate 1 week temperaturecontrolled environment 252C humidity 555 artificial 12h lightdark cycle free access food tap water Mice randomly divided groups n6group underwent sham operation bilateral OVX AgomirmiR1005p 5AAC CCG UAG AUC CGA ACU UGU G3 control agomir agomirCon 5AGU UUA GCU AAC GGU GAG CCG A3 purchased Guangzhou RiboBio Co Ltd Surgical operations performed sodium pentobarbital anesthesia 50 mgkg SigmaAldrich Merck KGaA intraperitoneal injection The sham group received surgical operation OVX group ovariectomy mice OVX group ovaries excised The groups follows Sham group shamoperated mice treated normal saline ii OVX group OVXoperated mice treated normal saline iii OVX agomirCon group OVXoperated mice treated agomirCon iv OVX agomirmiR group OVXoperated mice treated agomirmiR1005p 100 mgkg tail vein injection After 4week treatment agomirs twiceweek mice euthanized blood harvested heart Serum liver tibia samples immediately collected maintained 80C analysis Reverse transcriptionquantitative polymerase chain reaction RTqPCR Total RNA extracted RANKLstimulated precursor cells NCTC1469 cells liver tibia samples TRIzol Invitrogen Thermo Fisher Scientific Inc according manufacturers protocol RT performed TaqMan reverse transcription kit Applied Biosystems Thermo Fisher Scientific Inc according manufac turers protocol miR1005p detected TaqMan MicroRNA assay Applied Biosystems Thermo Fisher Scientific Inc according manufacturers protocol The thermocycling conditions follows 95C 10 min followed 40 cycles 95C 15 sec 60C 60 sec U6 small nuclear RNA endogenous control Relative miR1005p expression levels calculated 2ΔΔCq method 33 In addition 2 µg total RNA synthesize cDNA moloney murine leukemia virus reverse transcriptase Invitrogen Thermo Fisher Scientific Inc according INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 729 Table I Primers reverse transcriptionquantitative polymerase chain reaction Gene NFATc1 Ctsk MMP9 TRAP Runx2 Osterix Osteocalcin ALP OPG RANKL CA2 FGF21 GAPDH Forward primer 53 Reverse primer 53 GCGAAGCCCAAGTCTCTTTCC AGGCGGAGGTCGATGCCCCG ACGCAGACATCGTCATCCAG GCTACTTGCGGTTTCACTATGGA GGCAGGTGCTTCAGAACTGG TGAGCTGGAACGTCACGTGC CTCAGGGTTTCAGTGGTT CCCTCTCCAAGA CATATAACAC CACACACACTGGGGACTCTG CACAGCCCTCTCTCTTGAGC CATTACTGTCAGCAGCGAGCA CAGGGAGGATGGAACAGTGGTA CACCATGGAGAAGGCCGGGG GTATGGACCAGAATGTGA CACGATGATGTCACCCTCGATGT CAGGGACCACAACTCGTCAT TGGTCATTTCTTTGGGGCTTATCT GTGGTGGCAGGTAGGTATGG AAGAGGAGGCCAGCCAGACA TTTCCACGAGCACCCATC TTGCCCTGAGTGGTGTTG CAGCTGTGAGGAGAGGAAGG GACTGTGACCCCCTTCCATA GACGCCAGTTGTCCACCATC TGACACCCAGGATTTGAATGAC GACGGACACATTGGGGGTAG ALP alkaline phosphatase CA2 carbonic anhydrase 2 Ctsk cathepsin K FGF21 fibroblast growth factor 21 MMP9 matrix metalloproteinase9 NFATc1 nuclear factor activated T cells cytoplasmic 1 OPG osteoprotegrin RANKL receptor activator nuclear factorκB ligand Runx2 Runtrelated transcription factor 2 manufacturers protocol RTqPCR performed Applied Biosystems 7300 RealTime PCR Applied Biosystems Thermo Fisher Scientific Inc TaqMan Universal PCR Master Mix Thermo Fisher Scientific Inc The cycling conditions follows 95C 10 min followed 40 cycles 95C 15 sec 60C 30 sec 72C 30 sec final extension step 72C 3 min The relative mRNA expression levels calculated 2ΔΔCq method 33 normalized GAPDH The primers synthesized Invitrogen Thermo Fisher Scientific Inc sequences presented Table I Cell transfection plasmid constructs PremiRcontrol PremiRCon premiR1005p synthesized Guangzhou RiboBio Co Ltd Guangzhou China Osteoclast precursors 1x105 seeded 6well plates trans fected premiRCon 5AGU UUA GCU AAC GGU GAG C CG A3 premiR1005p 5AAC CCG UAG AUC CGA ACU UGU G3 Lipofectamine 2000 Invitrogen Thermo Fisher Scientifc Inc Waltham MA USA 48 h 37C final concentrations 100 nM according manufac turers protocol TRAP staining RANKLstimulated precursor cells tibia samples fixed 4 paraformaldehyde 20 min 24 h respectively room temperature Tibia histological sections 5 µm obtained following decalcification 05 M EDTA pH 80 embedded paraffin according standard histological procedures RANKLstimulated precursor cells tibia histological sections stained TRAP activity 01 M acetate solution pH 50 containing 676 mM sodium tartrate 01 mg ml naphthol ASMX phosphate 05 mgml Fast Red Violet The TRAP staining kit purchased SigmaAldrich Merck KGaA Darmstadt Germany TRAPpositive multinucleated cells nuclei scored visualized microscope Leica DM 2500 Leica Microsystems GmbH Wetzlar Germany Hematoxylin eosin HE staining Tibias fixed 4 formalin room temperature 24 h decalcified 05 M EDTA pH 80 embedded paraffin according standard histological procedures Tibia tissues cut 5 µm sections stained HE Beyotime Institute Biotechnology Haimen China according manufacturers protocol Stained slides visualized optical microscope Leica DM 2500 Leica Microsystems GmbH analyzed OsteoMeasure OsteoMetrics Inc Decatur GA USA Bone Ca content BMD Ca content tibia deter mined following incineration samples muffle furnace Thermo Fisher Scientific Inc 800C 12 h Subsequently 10 mg bone ash dissolved 1 ml 37 HCl diluted MilliQ water The Ca content determined kit cat C0043 Nanjing Jiancheng Bioengineering Institute Nanjing China according manufacturers protocol The BMD tibia measured dualenergy Xray absorptiometry Lunar DPXIQ GE Healthcare Chicago IL USA described previously 34 Physiological biochemical markers serum urine samples The levels FGF21 mouse serum detected mouse bioactive ELISA kit cat EELM0029c Elabscience Biotechnology Wuhan China according manufacturers protocol The levels Ca cat C0043 phosphorus P cat C006 creatinine cat C0111 serum urine samples measured kits Nanjing Jiancheng Bioengineering Institute according manu facturers protocol Parathyroid hormone cat 602305 Immutopics Inc San Clemente CA USA alkaline phospha tase cat EELM2720c ALP Elabscience Biotechnology 730 ZHOU et al miR1005p INHIBITS BONE LOSS Figure 1 RANKL induces osteoclast differentiation regulates miRNA expression A Schematic diagram representing process MCSF RANKLinduced osteoclastogenesis B Microarray hierarchical cluster analyses performed osteoclast precursors following MCSF RANKL stimulation 3 days The color legend indicates miRNA expression levels Red high expres sion green low expression C Validation microarray results regards miR1005p expression reverse transcriptionquantitative polymerase chain reaction analysis miR1005p expression normalized U6 expression D Protein expression TRAP detected western blotting response MCSF RANKLinduced osteoclas togenesis Triplicate experiments performed group P005 P001 P0001 MCSF macrophage colonystimulating factor miRNAmiR microRNA RANKL receptor activator nuclear factorκB ligand TRAP tartrateresistant acid phosphatase TRAP5b cat SBTR103 Immunodiagnostic Systems Inc Scottsdale AZ USA osteocalcin cat 60 1305 Immutopics Inc Cterminal telopeptide type 1 collagen CTX EELM0366c Elabscience Biotechnology detected mouse bioactive ELISA kits according manufacturers protocols Wester n blot t ng P rot ei ns ext ract e d f rom RANKLstimulated precursor cells NCTC1469 cells liver tibia samples radioimmunoprecipitation assay buffer Beyotime Institute Biotechnology Protein concen tration measured Bicinchoninic Acid kit protein determination cat BCA11KT SigmaAldrich Merck KGaA Western blotting conducted previously described 35 The membranes incubated following primary antibodies room temperature 2 h TRAP cat ab126775 12000 Abcam Cambridge UK RANK cat sc59981 11000 Santa Cruz Biotechnology Inc Dallas TX USA RANKL cat ab45039 11000 Abcam NFATc1 cat sc 7294 11000 Santa Cruz Biotechnology Inc FGF21 cat ab64857 11000 Abcam Following incubation primary antibodies membranes incubated room temperature 1 h appropriate horseradish peroxidaseconjugated antimouse secondary antibody cat sc516102 110000 Santa Cruz Biotechnology Inc antirabbit secondary antibody cat sc2357 110000 Santa Cruz Biotechnology Inc visualized chemiluminescence Thermo Fisher Scientific Inc βactin 12000 cat sc130065 Santa Cruz Biotechnology Inc control antibody Signals analyzed Quantity One software version 45 Bio Rad Laboratories Inc Hercules CA USA Luciferase reporter assay The wild type WT mutanttype MUT 3UTRs FGF21 synthesized Guangzhou RiboBio Co Ltd inserted multiple cloning sites luciferase expressing pMIRREPORT vector Ambion Thermo Fisher Scientific Inc according manufac turers protocol For luciferase assay BMMs 1x105 seeded 24wells cotransfected luciferase reporter vectors containing WT MUT 3UTR 05 µg FGF21 premiRCon premiR1005p 100 nM Lipofectamine 2000 Invitrogen Thermo Fisher Scientific Inc 37C 48 h Luciferase activity measured dual luciferase reporter assay kit Beyotime Institute Biotechnology according manufacturers protocol WT vector group normalize luciferase activity Statistical analysis Data presented means stan dard error mean Statistical analysis performed SPSS Statistics version 190 IBM Corp Armonk NY USA GraphPad Prism version 70 GraphPad Software Inc La Jolla CA USA Students ttest analyze differences groups Intergroup INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 731 Figure 2 miR1005p gainoffunction inhibits osteoclast differentiation A Expression levels miR1005p measured RTqPCR osteoclast precursors posttransfection premiR1005p prior RANKL stimulation Expression osteoclastspecific genes B NFATc1 C Ctsk D MMP9 E TRAP detected RTqPCR response MCSF RANKLinduced osteoclastogenesis premiR1005p transfection F Osteoclast precursor cells transfected premiR1005p cultured additional 3 days MCSF RANKL cultured cells fixed stained TRAP number osteoclasts counted Triplicate experiments performed group P005 Ctsk cathepsin K MCSF macrophage colonystimulating factor miRNAmiR microRNA MMP9 matrix metalloproteinase9 NFATc1 nuclear factor activated T cells cyto plasmic 1 premiRCon premiRcontrol RANKL receptor activator nuclear factorκB ligand RTqPCR reverse transcriptionquantitative polymerase chain reaction TRAP tartrateresistant acid phosphatase differences analyzed oneway analysis variance followed post hoc Tukey test multiple comparisons P005 considered indicate statistically significant difference Results miR10 0 5p downregulated R A NKL MCSFinduced osteoclastogenesis BMMs initially cultured MCSF 50 ngml 3 days induce formation osteoclast precursors stimulated MCSF 50 ngml RANKL 100 ngml 3 days induce osteoclastogenesis Fig 1A A miRNA microarray analysis conducted determine molecular mechanism involved RANKL MCSFinduced osteoclastogenesis The results demonstrated 31 miRNAs differentially expressed osteoclast precursors RANKL stimulation compared RANKL stimulation 13 18 miRNAs downregulated upregulated respectively Fig 1B The expression levels miR1005p significantly decreased RANKLstimulated cells In addition expression miR1005p validated RTqPCR results consistent microarray analysis indicated expression decreased timedependent manner response RANKL MCSFinduced osteoclastogenesis Fig 1C Furthermore protein expression levels TRAP significantly augmented process osteoclastogenesis Fig 1D Overexpression miR1005p suppresses RANKL MCSFinduced osteoclastogenesis To investigate function miR1005p vitro premiR1005p trans fected osteoclast precursors order amplify expression miR1005p results revealed significant upregulation 120fold miR1005p osteoclast precur sors Fig 2A Posttransfection premiR1005p 732 ZHOU et al miR1005p INHIBITS BONE LOSS Table II Biochemical parameters OVXoperated mice treated agomirmiR Parameters Sham OVX OVX agomircon OVX agomirmiR Serum Ca mgdl Serum P mgdl Urine CaCre mgmg Urine PCre mgmg ALP ngml Osteocalcin ngml TRAP5b Ul CTX ngml Serum PTH pgml 1067043 606031 01140012 141020 305023 1293153 894042 1537166 1233245 912040a 612035 02230027a 139026 190021a 767161a 1275054a 2757287a 2563356a 937032 625036 02070021 155033 175026 687123 1270058 2690222 2713332 1093045b 617032 01330016b 153031 382030 110395b 1009045b 1243083b 1713266b AgomirCon control agomir agomirmiR miR1005p agomir ALP alkaline phosphatase Ca calcium Cre creatinine CTX Cterminal telopeptide type 1 collagen miR microRNA OVX ovariectomy P phosphorus PTH parathyroid hormone TRAP5b tartrateresistant acid phosphatase 5b aP005 vs shamoperated group bP005 vs OVX AgomirCon group key transcription factor osteoclastogenesis NFATc1 Fig 2B osteoclastspecific genes Ctsk Fig 2C matrix metalloproteinase9 MMP9 Fig 2D TRAP Fig 2E significantly decreased compared premiRCon group Furthermore osteoclast differen tiation TRAPpositive multinucleated cells blocked premiR1005p Fig 2F These findings indicated miR1005p suppressor neutralize RANKL MCSFinduced osteoclastogenesis AgomirmiR1005p blocks OVXinduced bone resorption The present study examined overexpression miR1005p regulates bone metabolism vivo Osteoporotic status induced OVX mice OVXoperated mice administered agomirmiR1005p agomirCon tail vein injection ELISA analyses revealed bone formation markers ALP osteocalcin bone resorption markers TRAP5b CTX downregulated upregulated respectively OVXoperated mice Conversely agomirmiR1005p treatment reversed OVXinduced marker alterations exception serum ALP Table II RTqPCR analysis revealed miR1005p levels significantly downregulated tibia OVXoperated mice compared tibia shamoperated mice OVXoperated mice injected agomirmiR1005p OVXinhibited miR1005p levels markedly rescued tibia Fig 3A Subsequently mRNA expression levels osteoblastspecific genes Runtrelated transcription factor 2 Runx2 osterix osteocalcin ALP detected confirmed genes reduced tibia OVXoperated mice agomirmiR1005p administration OVXoperated mice significantly upregulated mRNA expression levels Runx2 osterix osteocalcin ALP Fig 3B Conversely mRNA ratio RANKLosteoprotegrin OPG elevated tibia OVXoperated mice suggesting increase osteoclast activity OVXoperated mice associated overactivation RANKL availability upregulation RANKLOPG ratio reversed agomirmiR1005p administration OVXoperated mice Fig 3C To investigate miR1005p inhibited OVXinduced bone resorption osteoclastspecific genes NFATc1 Ctsk MMP9 carbonic anhydrase 2 CA2 TRAP detected RTqPCR results demonstrated agomirmiR1005p treatment markedly abolished OVXinduced upregulation osteoclastspecific genes tibia Fig 3D In addition determined western blotting OVXoperated mice exhibited significant increase RANK RANKL NFATc1 agomirmiR1005p administration decreased protein expression levels RANK RANKL NFATc1 tibia OVXoperated miceFig 3E 3F Ca P metabolism analyzed OVXoperated mice response agomirmiR1005p administration Compared agomirCon treated OVXoperated mice agomirmiR1005p administration significantly increased serum Ca concentration blocked urinary Ca secretion serum urine levels P markedly altered response OVX operation agomirmiR1005p administration Table II Bone Ca content tibia BMD decreased OVX increased agomirmiR1005p administration OVXoperated mice Fig 4A B Histomorphological observation HE staining revealed integrity trabecular bone microstructure network destroyed proximal epiphysis tibia OVX However agomirmiR1005p administration markedly improved trabecular bone structure accelerated bone remodeling Fig 4C D Furthermore function agomirmiR1005p osteoclast differentiation determined vivo TRAP staining revealed number osteoclasts increased OVX osteoclast numbers significantly decreased agomirmiR1005p treatment Fig 4E F Collectively findings suggested increased bone mass agomirmiR1005padministered OVXoperated mice caused combination increased bone formation decreased bone resorption AgomirmiR1005p abolishes OVXinduced FGF21 liver Previous studies reported FGF21 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 733 Figure 3 AgomirmiR regulates osteoblast osteoclastspecific gene expression OVXoperated mice A Mice OVX group injected intra venously agomirmiR1005p agomirCon expression levels miR1005p measured RTqPCR tibia B Osteoblastspecific genes Runx2 osterix osteocalcin ALP detected tibia RTqPCR C Ratio RANKL mRNA OPG mRNA tibia cal culated marker osteoclast activity D RTqPCR performed analyze mRNA expression levels osteoclastspecific genes tibia E F Protein expression levels RANK RANKL NFATc1 tibia detected western blotting Triplicate experiments performed group P005 agomirmiR miR1005p agomir agomirCon control agomir CA2 carbonic anhydrase 2 Ctsk cathepsin K miR microRNA MMP9 matrix metalloproteinase9 NFATc1 nuclear factor activated T cells cytoplasmic 1 OPG osteoprotegrin OVX ovariectomy RANK receptor activator nuclear factorκB RANKL RANK ligand RTqPCR reverse transcriptionquantitative polymerase chain reaction TRAP tartrateresistant acid phosphatase inducible liver absent bone indirectly promotes osteoclastogenesis bone resorption simultaneously decreasing bone formation increasing bone resorption 2630 To determine association miR1005p FGF21 agomirmiR1005p agomirCon injected OVXoperated mice tail vein 734 ZHOU et al miR1005p INHIBITS BONE LOSS Figure 4 AgomirmiR inhibits bone loss tibia OVXoperated mice A Bone Ca content B tibia BMD measured OVXoperated mice treated agomirmiR agomirCon injection C Hematoxylin eosin staining performed assess effects agomirmiR trabecular bone microstructure proximal tibia OVXoperated mice magnification x200 scale bar 25 µm D Ratio trabecular bone area total area proximal tibia calculated estimate trabecular bone metabolism E TRAP staining magnification x100 scale bar 50 µm F number osteoclasts tibia measured assess effects agomirmiR osteoclast activity black arrows represent mature osteoclasts Triplicate experi ments performed group P005 AgomirCon control agomir agomirmiR miR1005p agomir BMD bone mineral density Ca calcium miR microRNA OVX ovariectomy TRAP tartrateresistant acid phosphatase results revealed miR1005p significantly decreased liver OVXoperated mice compared shamoperated group agomirmiR1005p injection rescued OVXinduced downregulation miR1005p expression liver Fig 5A Consistent previous findings 2630 present results indicated significant increase mRNA expression Fig 5B serum levels Fig 5C protein expression Fig 5D E FGF21 liver OVXoperated mice Notably liver serum FGF21 levels suppressed agomirmiR1005p injection OVXoperated mice Fig 5BE To investigate FGF21 direct target miR1005p online prediction software TargetScan httpwwwtargetscanorgvert_72 predict association miR1005p FGF21 It revealed 3UTR FGF21 contained conserved binding site miR1005p presented complementary pairing Fig 6A To confirm finding luciferase reporter plasmids containing WT MUT 3UTR FGF21 cotransfected premiRCon premiR1005p NCTC1469 mouse normal liver cell line The results revealed luciferase activity reduced 60 cells transfected plasmids containing WT 3UTR FGF21 premiR1005p premiR1005p effect luciferase activity cells transfected plasmids containing MUT 3UTR FGF21 Fig 6B Furthermore identify action miR1005p FGF21 NCTC1469 cells transfected premiRCon premiR1005p mRNA protein expression levels FGF21 measured Compared premiRCon group overexpression miR1005p significantly downregulated mRNA protein expression levels FGF21 Fig 6C D These findings suggested FGF21 direct target miR1005p INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 735 Figure 5 Mice OVX group injected intravenously agomirmiR agomirCon A miR1005p expression liver measured RTqPCR B mRNA expression FGF21 liver tibia measured RTqPCR C serum levels FGF21 measured ELISA D E protein expression TRAP liver detected western blotting Triplicate experiments performed group P005 AgomirCon control agomir agomirmiR miR1005p agomir FGF21 fibroblast growth factor 21 nd detected OVX ovariectomy TRTqPCR reverse transcriptionquantitative polymerase chain reaction TRAP tartrateresistant acid phosphatase Figure 6 FGF21 direct target miR1005p A Putative miR1005p binding sites 3UTR FGF21 predicted bioinformatics analysis B Luciferase activity assay performed posttransfection premiR1005p premiRCon NCTC1469 cell WT MUT 3UTR FGF21 C mRNA D protein expression levels FGF21 assessed reverse transcriptionquantitative polymerase chain reaction western blotting respectively posttransfection premiR1005p premiRCon NCTC1469 cells Triplicate experiments performed group P005 3UTR 3untranslated region Con control FGF21 fibroblast growth factor 21 miR microRNA MUT mutanttype premiRCon premiRcontrol WT wild type Based aforementioned findings revealed miR1005p inhibited process osteo clastogenesis vitro OVXinduced bone loss vivo FGF21 potential proosteoclastogenic liver hormone involved RANKLRANKNFATc1 cascade signalingmediated osteoclast differentiation agomirmiR1005p posttranscriptional regulatory factor targeted FGF21RANKLRANKNFATc1 pathway block osteoclastogenesis OVXinduced bone loss Fig 7 736 Discussion ZHOU et al miR1005p INHIBITS BONE LOSS The present study confirmed expression miR1005p downregulated RANKLinduced osteoclastogenesis determined microarray RTqPCR analyses miR1005p gainoffunction markedly inhibited process osteoclast differentiation negatively regulated osteoclast function suppressing mRNA expression levels osteoclastspecific genes vitro The present results suggested Ca metabolism trabecular bone remodeling improved osteoclast differentiation activity decreased agomirmiR1005p OVXoperated mice Furthermore crucial liver hormone FGF21 upregulated involved OVXinduced bone resorption Notably agomirmiR1005p abrogated OVXinduced upregulation FGF21 liver serum FGF21 validated direct target miR1005p bioinformatics analysis luciferase activity assay Overexpression miR1005p resulted downregulation FGF21 mRNA protein expression NCTC1469 cells Based findings suggested agomirmiR1005p alleviated osteoclast differentiation bone loss blocking liversecreted FGF21 FGF21 lead overactivation RANKLRANKNFATc1 signaling pathway mediating osteoclastic bone resorption miRNAs posttranscriptional regulators mediate expression bone metabolismassociated genes tran scriptional translational levels 91113 For example overexpression miR503 prevents bone resorption osteoclast activity vitro vivo inhibiting RANK expression 11 miR34a key osteoclast suppressor blocks osteoporosis suppressing transforming growth factorβinduced factor 2 mice 9 Furthermore miR214 leads decline bone formation inhibiting acti vating transcription factor 4 phosphatase tensin homolog 1013 These results suggested regulatory mechanism including numerous miRNAs miRNA target genes involved process osteoclas togenesis bone loss 91113 A previous study reported miR100 modulates human mesenchymal stem cell MSC differentiation osteoblasts promotes osteo genesis response mechanical stress 36 Conversely miR100 serves negative role osteogenic differentiation derived human adiposederived MSCs targeting bone morphogenetic protein receptor type II 18 The present study revealed downregulation miR1005p accompanied increase expression levels FGF21 liver samples OVXoperated mice Further investigations indicated FGF21 direct target miR1005p inhibit FGF21 levels serum liver osteoclast activity bone loss suppressed agomirmiR1005p injection OVXoperated mice These observations provided insight liverbone endocrine signaling suggested miR1005p targeted FGF21 inhibit hepatic expression contributed regeneration bone pathophysiological condi tions FGF21 hepatokine mainly expressed liver 2630 FGF21 considered potential novel drug treatment obesity diabetes potentiating effect Figure 7 Schematic diagram miR1005p mediate suppres sion osteoclastogenesis targeting hepatokine FGF21 CA2 carbonic anhydrase 2 Ctsk cathepsin K FGF21 fibroblast growth factor 21 miR microRNA MMP9 matrix metalloproteinase9 NFATc1 nuclear factor activated T cells cytoplasmic 1 RANK receptor activator nuclear factorκB RANKL RANK ligand peroxisome proliferatoractivated receptor γ PPARγ 37 Furthermore FGF21 inhibits osteoblastogenesis MSCs stimulates osteoclastogenesis hematopoietic stem cells activating PPARγ bone mass markedly restored FGF21 deletion 2637 A previous study 36 present findings revealed miR1005p exerted opposite effect FGF21 osteoclast differentiation A functional study revealed FGF21 direct target miR1005p agomirmiR1005p effectively blocked FGF21 secretion liver inhibited osteoclastogenesis osteoclastspecific gene expression stimulated bone formation osteoblastspecific gene expression FGF21 inducible liver absent bone suggesting FGF21stimulated osteoclast differentiation bone loss mediated liverbone endocrine metabolic mecha nism OVXoperated mice In conclusion present results demonstrated altera tions expression levels miR1005p lead alteration bone homeostasis osteoclast differentiation These phenomena associated hepatokine FGF21 The present experimental evidence vitro vivo studies strongly indicated miR1005p prevent bone resorption osteoclastogenesis partially inhibition FGF21 secretion liver This finding provide novel insight management osteoporosis osteoclastassociated bone diseases Acknowledgements Not applicable Funding The present study supported National Natural Science Foundation China grant 81370981 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 43 727738 2019 737 Availability data materials All data generated analyzed study included published article Authors contributions The study designed LZ HYS LLG LYY SM QF Literature research data acquisition data analysis performed LZ HYS QF Histological examina tion conducted LLG LYY SM Western blotting RTqPCR performed LZ HYS QF The manuscript prepared edited LZ HYS LLG LYY SM QF The manuscript reviewed LZ HYS LLG LYY SM QF QF approved final version manu script Ethics approval consent participate The present study approved Animal Ethical Committee Shengjing Hospital China Medical University approval 2016PS361K Patient consent publication Not applicable Competing interests The authors declare competing interests References 1 Yuan FL Wu QY Miao ZN Xu MH Xu RS Jiang DL Ye JX Chen FH Zhao MD Wang HJ Li X Osteoclastderived extracellular vesicles Novel regulators osteoclastogenesis osteoclastosteoblasts communication bone remodeling Front Physiol 9 628 2018 2 Neman J Hambrecht A Cadry C Jandial R Stem cellmediated osteogenesis Therapeutic potential bone tissue engineering Biologics 6 4757 2012 3 Xiao W Wang Y Pacios S Li S Graves DT Cellular molecular aspects bone remodeling Front Oral Biol 18 916 2016 4 Deng L Wang Y Peng Y Wu Y Ding Y Jiang Y Shen Z Fu Q Osteoblastderived microvesicles A novel mechanism communication osteoblasts osteoclasts Bone 79 3742 2015 5 Siddiqi MH Siddiqi MZ Ahn S Kang S Kim YJ Sathishkumar N Yang DU Yang DC Ginseng saponins treatment osteoporosis Mini literature review J Ginseng Res 37 261268 2013 6 Collison J Bone miR106b promotes osteoporosis mice Nat Rev Rheumatol 13 130 2017 7 Szabo G Bala S MicroRNAs liver disease Nat Rev Gastroenterol Hepatol 10 542552 2013 8 Rottiers V Naar AM MicroRNAs metabolism metabolic disorders Nat Rev Mol Cell Biol 13 239250 2012 9 Krzeszinski JY Wei W Huynh H Jin Z Wang X Chang TC Xie XJ He L Mangala LS LopezBerestein G et al miR34a blocks osteoporosis bone metastasis inhibiting osteoclas togenesis Tgif2 Nature 512 431435 2014 10 Wang X Guo B Li Q Peng J Yang Z Wang A Li D Hou Z Lv K Kan G et al miR214 targets ATF4 inhibit bone formation Nat Med 19 93100 2013 11 Chen C Cheng P Xie H Zhou HD Wu XP Liao EY Luo XH MiR503 regulates osteoclastogenesis targeting RANK J Bone Miner Res 29 338347 2014 12 Guo LJ Liao L Yang L Li Y Jiang TJ MiR 125a TNF receptorassociated factor 6 inhibit osteoclastogenesis Exp Cell Res 321 142152 2014 13 Zhao C Sun W Zhang P Ling S Li Y Zhao D Peng J Wang A Li Q Song J et al miR214 promotes osteoclastogenesis targeting PtenPI3kAkt pathway RNA Biol 12 343353 2015 14 Jin Y Tymen SD Chen D Fang ZJ Zhao Y Dragas D Dai Y Marucha PT Zhou X MicroRNA99 family targets AKTmTOR signaling pathway dermal wound healing PLoS One 8 e64434 2013 15 Lu Y Zhao X Liu Q Li C GravesDeal R Cao Z Singh B Franklin JL Wang J Hu H et al lncRNA MIR100HGderived miR100 miR125b mediate cetuximab resistance Wntβcatenin signaling Nat Med 23 13311341 2017 16 Liu M Han T Shi S Chen E Long noncoding RNA HAGLROS regulates cell apoptosis autophagy lipopolysaccharidesinduced WI38 cells modulating miR100NFκB axis Biochem Biophys Res Commun 500 589596 2018 17 Seeliger C Karpinski K Haug AT Vester H Schmitt A Bauer JS van Griensven M Five freely circulating miRNAs bone tissue miRNAs associated osteoporotic fractures J Bone Miner Res 29 17181728 2014 18 Zeng Y Qu X Li H Huang S Wang S Xu Q Lin R Han Q Li J Zhao RC MicroRNA100 regulates osteogenic differ entiation human adiposederived mesenchymal stem cells targeting BMPR2 FEBS Lett 586 23752381 2012 19 Liu J Xu Y Hu Y Wang G The role fibroblast growth factor 21 pathogenesis nonalcoholic fatty liver disease implications therapy Metabolism 64 380390 2015 20 Charoenphandhu N Suntornsaratoon P Krishnamra N SaNguanmoo P Tanajak P Wang X Liang G Li X Jiang C Chattipakorn N Chattipakorn S Fibroblast growth factor21 restores insulin sensitivity induces aberrant bone micro structure obese insulinresistant rats J Bone Miner Metab 35 142149 2017 21 Anuwatmatee S Tang S Wu BJ Rye KA Ong KL Fibroblast growth factor 21 chronic kidney disease Clin Chim Acta S00098981 304321 2017 22 Planavila A Redondo I Hondares E Vinciguerra M Munts C Iglesias R Gabrielli LA Sitges M Giralt M van Bilsen M Villarroya F Fibroblast growth factor 21 protects cardiac hypertrophy mice Nat Commun 4 2019 2013 23 Desai BN Singhal G Watanabe M Stevanovic D Lundasen T Fisher FM Mather ML Vardeh HG Douris N Adams AC et al Fibroblast growth factor 21 FGF21 robustly induced ethanol protective role ethanol associated liver injury Mol Metab 6 13951406 2017 24 Li H Dong K Fang Q Hou X Zhou M Bao Y Xiang K Xu A Jia W High serum level fibroblast growth factor 21 independent predictor nonalcoholic fatty liver disease A 3year prospective study China J Hepatol 58 557563 2013 25 Samson SL Sathyanarayana P Jogi M Gonzalez EV Gutierrez A Krishnamurthy R Muthupillai R Chan L Bajaj M Exenatide decreases hepatic fibroblast growth factor 21 resistance nonalcoholic fatty liver disease mouse model obesity randomised controlled trial Diabetologia 54 30933100 2011 26 Wei W Dutchak PA Wang X Ding X Wang X Bookout AL Goetz R Mohammadi M Gerard RD Dechow PC et al Fibroblast growth factor 21 promotes bone loss potentiating effects peroxisome proliferatoractivated receptor γ Proc Natl Acad Sci USA 109 31433148 2012 27 Hao RH Gao JL Li M Huang W Zhu DL Thynn HN Dong SS Guo Y Association fibroblast growth factor 21 bone mineral density adults Endocrine 59 296303 2018 28 GallegoEscuredo JM Lamarca MK Villarroya J Domingo JC Mateo MG Gutierrez MDM Vidal F Villarroya F Domingo P Giralt M High FGF21 levels associated altered bone homeostasis HIV1infected patients Metabolism 71 163170 2017 29 Lee P Linderman J Smith S Brychta RJ Perron R Idelson C Werner CD Chen KY Celi FS Fibroblast growth factor 21 FGF21 bone Is relationship humans Osteoporos Int 24 30533057 2013 30 Wang X Wei W Krzeszinski JY Wang Y Wan Y A liverbone endocrine relay IGFBP1 promotes osteoclasto genesis mediates FGF21induced bone resorption Cell Metab 22 811824 2015 738 ZHOU et al miR1005p INHIBITS BONE LOSS 31 Zhao H Zhang J Shao H Liu J Jin M Chen J Huang Y Transforming growth factor β1Smad4 signaling affects osteoclast differentiation regulation miR155 expression Mol Cells 40 211221 2017 32 Saeed AI Sharov V White J Li J Liang W Bhagabati N Braisted J Klapa M Currier T Thiagarajan M et al TM4 A free opensource microarray data management analysis Biotechniques 34 374378 2003 33 Livak KJ Schmittgen TD Analysis relative gene expression data realtime quantitative PCR 2Delta Delta CT method Methods 25 402408 2001 34 Gargiulo S Gramanzini M Megna R Greco A Albanese S Manfredi C Brunetti A Evaluation growth patterns body composition C57Bl6J mice dual energy Xray absorptiometry Biomed Res Int 2014 253067 2014 35 Yu FY Xie CQ Sun JT Peng W Huang XW Overexpressed miR145 inhibits osteoclastogenesis RANKLinduced bone marrowderived macrophages ovariectomized mice regu lation Smad3 Life Sci 202 1120 2018 36 Frith JE Kusuma GD Carthew J Li F Cloonan N Gomez GA CooperWhite JJ Mechanicallysensitive miRNAs bias human mesenchymal stem cell fate mTOR signalling Nat Commun 9 257 2018 37 Wan Y Bone marrow mesenchymal stem cells Fat blast FGF21 Int J Biochem Cell Biol 45 546549 2013 This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40 License